糖尿病状态下阿司匹林抵抗的研究进展

摘要/Abstract

摘要： 阿司匹林作为抗血小板聚集治疗的“金标准”,在预防心脑血管栓塞性疾病方面起着重要的作用。然而在服用阿司匹林后,并非所有的患者均能获得一致的抗血小板聚集效益。临床上,服用治疗剂量的阿司匹林后仍出现心血管事件的现象被称为“阿司匹林抵抗 (aspirin resistance,AR)”。发生阿司匹林抵抗的患者中有相当一部分是糖尿病患者。尽管很多糖尿病患者服用阿司匹林进行心血管疾病的一级预防,但获益很低。对于非糖尿病患者,阿司匹林可以降低41%的心血管事件。而在糖尿病患者中心血管事件发生率仅降低了10%。虽然研究显示糖尿病同阿司匹林抵抗高度相关,然而糖尿病患者中高阿司匹林抵抗发生率的原因还不清楚。本文拟就糖尿病患者的阿司匹林抵抗机制及其逆转方法进行探讨。

关键词: 糖尿病, 阿司匹林抵抗, 血小板

Abstract: Aspirin is the “gold standard” of antiplatelet therapy. It plays a very important role in the prevention of cardiovascular disease. However, not all the patients can respond a consistent anti-aggregation effect after they take aspirin. Clinically, this phenomenon that therapeutic dose of aspirin can not prevent the cardiovascular events is called “aspirin resistance (AR)”. A considerable portion of aspirin resistance patients also have diabetes or insulin resistance. Many diabetic patients take aspirin for primary prevention of cardiovascular disease, but the benefit is low. Aspirin can reduce the risk of cardiovascular events by 41% in non-diabetic patients. But the risk reduction in the subgroup with diabetes was only 10%.Although diabetes has been recognised as a high risk factor of aspirin resistance, the mechanism under the high diabetic prevalence in aspirin resistance patients is unclear. This paper will review the mechanisms of aspirin resistance in diabetic statue and explore methods to reverse it.

Key words: diabetes, aspirin resistance, platelet

中图分类号:

R587.1

谢昊, 朱语眉, 郝海平, 郑啸, 马思静, 王广基. 糖尿病状态下阿司匹林抵抗的研究进展[J]. 中国临床药理学与治疗学, 2014, 19(2): 233-240.

XIE Hao, ZHU Yu-mei, HAO Hai-ping, ZHENG Xiao, MA Si-jing, WANG Guang-ji. Research progress of aspirin resistance in diabetic statue[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(2): 233-240.

参考文献

[1] 张建华,叶玲丽,赵玮,等.冠心病患者生化阿司匹林抵抗的临床研究[J].中国临床药理学与治疗学,2007,12(12):1436-1440.
[2] Fateh-Moghadam S, Plockinger U, Cabeza N, et al, Prevalence of aspirin resistance in patients with type 2 diabetes[J].Acta Diabetol,2005, 42(2): 99-103.
[3] Ertugrul DT, Tutal E, Yildiz M, et al. Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus[J]. J Clin Endocrinol Metab, 2010, 95(6): 2897-2901.
[4] Sarwar N,Gao P,Seshasai SR,et al.Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies[J].Lancet,2010, 375(9733): 2215-2222.
[5] Shah B,Sha DH,Xie DW,et al. The relationship between diabetes, metabolic syndrome, and platelet activity as measured by mean platelet volume the national health and nutrition examination survey, 1999-2004[J].Diabetes Care,2012, 35(5): 1074-1078.
[6] Yngen M, Ostenson CG,Hu H,et al.Enhanced P-selectin expression and increased soluble CD40 Ligand in patients with Type 1 diabetes mellitus and microangiopathy: evidence for platelet hyperactivity and chronic inflammation[J].Diabetologia,2004, 47(3): 537-540.
[7] Gresner P, Dolnik M,Waczulikova I,et al.Increased blood plasma hydrolysis of acetylsalicylic acid in type 2 diabetic patients: a role of plasma esterases[J].Biochim Biophys Acta,2006, 1760(2): 207-215.
[8] Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients[J].BMJ,2002, 324(7329): 71-86.
[9] Belch J, MacCuish A,Campbell I,et al.The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease[J].BMJ,2008, 337:a1840.
[10] Ogawa H, Nakayama M,Morimoto T,et al.Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial[J].JAMA,2008, 300(18): 2134-2141.
[11] Watala C, Pluta J,Golanski J, et al.Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin[J].J Mol Med (Berl),2005, 83(2): 148-158.
[12] Sobal G, Menzel JE, Sinzinger H.Influence of acetylsalicylic acid on oxidation of native and glycated low-density lipoprotein[J].Life Sci,2000, 66(20): 1987-1998.
[13] Hangaishi M, Taguchi J,Miyata T,et al.Increased aggregation of human platelets produced by advanced glycation end products in vitro[J].Biochem Biophys Res Commun,1998, 248(2): 285-292.
[14] Watala C, Ulicna O, Golanski J, et al.High glucose contributes to aspirin insensitivity in streptozotocin-diabetic rats: a multiparametric aggregation study[J].Blood Coagul Fibrinolysis,2006, 17(2): 113-124.
[15] Kobzar G, Mardla V,Samel N.Short-term exposure of platelets to glucose impairs inhibition of platelet aggregation by cyclooxygenase inhibitors[J].Platelets,2011, 22(5): 338-344.
[16] Riondino S, TrifiroE,Principessa L, et al. Lack of biological relevance of platelet cyclooxygenase-2 dependent thromboxane A2 production[J].Thromb Res,2008, 122(3): 359-365.
[17] Davi G,Catalano I,Averna M, et al.Thromboxane biosynthesis and platelet function in type II diabetes mellitus[J].N Engl J Med,1990, 322(25): 1769-1774.
[18] Alzahrani SH, Ajjan RA.Coagulation and fibrinolysis in diabetes[J].Diab Vasc Dis Res,2010, 7(4): 260-273.
[19] Russo I, Viretto M,Barale C,et al.High glucose inhibits the aspirin-induced activation of the nitric oxide/cGMP/cGMP-dependent protein kinase pathway and does not affect the aspirin-induced inhibition of thromboxane synthesis in human platelets[J].Diabetes,2012, 61(11): 2913-2921.
[20] O'Kane PD, Queen LR, Ji Y, et al.Aspirin modifies nitric oxide synthase activity in platelets: effects of acute versus chronic aspirin treatment[J].Cardiovasc Res,2003, 59(1): 152-159.
[21] Watala C,Golanski J, PlutaJ, et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control[J].Thromb Res,2004, 113(2): 101-113.
[22] TschoepeD, Roesen P, Esser J,et al.Large platelets circulate in an activated state in diabetes mellitus[J].Semin Thromb Hemost,1991, 17(4): 433-438.
[23] Lordkipanidze M, Harrison P.Aspirin twice a day keeps new COX-1 at bay[J].J Thromb Haemost,2012, 10(7): 1217-1219.
[24] Ames PR, Batuca JR, MuncyIJ, et al.Aspirin insensitive thromboxane generation is associated with oxidative stress in type 2 diabetes mellitus[J].Thromb Res,2012, 130(3): 350-354.
[25] Takenaka T, TakahashiK, KobayashiT, et al.Oxidized low density lipoprotein (Ox-LDL) as a marker of atherosclerosis in hemodialysis (HD) patients[J].Clin Nephrol,2002, 58(1): 33-37.
[26] Chen LY, Mehta P,Mehta JL.Oxidized LDL decreases L-arginine uptake and nitric oxide synthase protein expression in human platelets: relevance of the effect of oxidized LDL on platelet function[J].Circulation,1996, 93(9): 1740-1746.
[27] Liani R,Halvorsen B, Sestili S.et al. Plasma levels of soluble CD36, platelet activation, inflammation, and oxidative stress are increased in type 2 diabetic patients[J].Free Radic Biol Med,2012, 52(8): 1318-1324.
[28] Trovati M, Anfossi G, Cavalot F, et al. Insulin directly reduces platelet sensitivity to aggregating agents. Studies in vitro and in vivo[J].Diabetes,1988, 37(6): 780-786.
[29] Hiramatsu K, Nozaki H, Arimori S.Reduction of platelet aggregation induced by euglycaemic insulin clamp[J].Diabetologia,1987, 30(5): 310-313.
[30] Trovati M, Anfossi G,Massucco P,et al. Insulin stimulates nitric oxide synthesis in human platelets and, through nitric oxide, increases platelet concentrations of both guanosine-3', 5'-cyclic monophosphate and adenosine-3', 5'-cyclic monophosphate[J].Diabetes,1997, 46(5): 742-749.
[31] Schwarz R, Walter U, Eigenthaler M.Taming platelets with cyclic nucleotides[J].Biochem Pharmacol,2001, 62(9): 1153-1161.
[32] Nishikawa T, Edelstein D, Du XL, et al.Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage[J].Nature,2000, 404(6779): 787-790.
[33] Pieper GM,Riazul H.Activation of nuclear factor-kappaB in cultured endothelial cells by increased glucose concentration: prevention by calphostin C[J].J Cardiovasc Pharmacol,1997, 30(4): 528-532.
[34] Evangelista V, Totani L,Rotondo S,et al. Prevention of cardiovascular disease in type-2 diabetes: how to improve the clinical efficacy of aspirin[J].Thromb Haemost,2005, 93(1): 8-16.
[35] Bochner F, Williams DB, Morris PM, et al.Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function[J].Eur J Clin Pharmacol,1988, 35(3): 287-294.
[36] LemkesBA, Bahler L, Kamphuisen PW, et al. The influence of aspirin dose and glycemic control on platelet inhibition in patients with type 2 diabetes mellitus[J].J Thromb Haemost,2012, 10(4): 639-646.
[37] Bliden KP, Tantry US, DiChiara J, et al. Further ex vivo evidence supporting higher aspirin dosing in patients with coronary artery disease and diabetes[J].Circ Cardiovasc Interv,2011, 4(2): 118-120.
[38] Cotter G, Shemesh E, Zehavi M, et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin [J] ?Am Heart J,2004, 147(2): 293-300.
[39] Catalano PM, Smith JB, Murphy S.Platelet recovery from aspirin inhibition in vivo; differing patterns under various assay conditions[J].Blood,1981, 57(1): 99-105.
[40] Schwartz KA, Schwartz DE, GhoshehK, et al. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction[J]. Am J Cardiol, 2005, 95(8): 973-975.
[41] 孙安修, 刘阳晨,顾玲,等.阿司匹林用药依从性的干预研究[J].中国临床药理学与治疗学,2009,14(10):1156-1159.
[42] Bauriedel G, Skowasch D, SchneiderM, et al.Antiplatelet effects of angiotensin-converting enzyme inhibitors compared with aspirin and clopidogrel: a pilot study with whole-blood aggregometry[J].Am Heart J,2003, 145(2): 343-348.
[43] Reavey-Cantwell JF, Fox WC, Reichwage BD, et al.Factors associated with aspirin resistance in patients premedicated with aspirin and clopidogrel for endovascular neurosurgery[J].Neurosurgery,2009, 64(5): 890-895; discussion 895-896.
[44] Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation[J].Diabetes Care,2010, 33(6): 1395-1402.
[45] Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects[J].J Am Coll Cardiol,2005, 45(8): 1295-1301.
[46] Cryer B, Berlin RG, Cooper S, et al, Double-blind, randomized, parallel, placebo-controlled study of ibuprofen effects on thromboxane B2 concentrations in aspirin-treated healthy adult volunteers[J].Clin Ther,2005, 27(2): 185-191.
[47] Cox D, Maree AO, Dooley M, et al. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers[J].Stroke,2006, 37(8): 2153-2158.
[48] Grosser T, Fries S, Lawson JA, et al.Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin[J].Circulation,2013, 127(3): 377-385.
[49] Macchi L, Christiaens L, Brabant S, et al.Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate[J].Thromb Res,2002, 107(1/2): 45-49.
[50] Farré A JL, Tamargo J, Mateos-Cáceres PJ, et al. Old and new molecular mechanisms associated with platelet resistance to antithrombotics[J]. Pharm Res, 2010, 27(11): 2365-2373.
[51] Gonzalez-Conejero R, Rivera J, Corral J, et al.Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure [J] ?Stroke,2005, 36(2): 276-280.
[52] Cipollone F, Toniato E, Martinotti S, et al.A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke[J].JAMA,2004, 291(18): 2221-2228.
[53] Takahashi S, Ushida M, Komine R, et al.Platelet responsiveness to in vitro aspirin is independent of COX-1 and COX-2 protein levels and polymorphisms[J].Thromb Res,2008, 121(4): 509-517.
[54] GoodmanT, FerroA,Sharma P.Pharmacogenetics of aspirin resistance: a comprehensive systematic review[J].Br J Clin Pharmacol,2008, 66(2): 222-232.
[55] Papp E, Havasi V, Bene J, et al.Glycoprotein IIIA gene (PlA) polymorphism and aspirin resistance: is there any correlation [J] ?Ann Pharmacother,2005, 39(6): 1013-1018.
[56] Ferroni P, Basili S, Santilli F, et al. Low-density lipoprotein-lowering medication and platelet function[J].Pathophysiol Haemost Thromb,2006, 35(3/4): 346-354.
[57] Schnell O, Erbach M, Hummel M. Primary and secondary prevention of cardiovascular disease in diabetes with aspirin[J].Diab Vasc Dis Res,2012, 9(4): 245-255.
[58] Santilli F, Davi G, ConsoliA, et al. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus[J].J Am Coll Cardiol,2006, 47(2): 391-397.
[59] Linden MD. Toward a guided approach to platelet activation in diabetes[J].J Thromb Thrombolysis,2013, 35(2): 175-177.
[60] Mongan J, Mieszczanska HZ, Smith BH, et al. Pioglitazone inhibits platelet function and potentiates the effects of aspirin: a prospective observation study[J].Thromb Res,2012, 129(6): 760-764.
[61] Postula M, Rosiak M, Kaplon-Cieslicka A, et al. Do statins influence platelet reactivity on acetylsalicylic acid therapy in patients with type 2 diabetes [J] ?Cardiol J,2012, 19(5): 494-500.
[62] Lee PY, Chen WH, Ng W, et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease[J].Am J Med,2005, 118(7): 723-727.
[63] Pignone M ,Williams CD. Aspirin for primary prevention of cardiovascular disease in diabetes mellitus[J].Nat Rev Endocrinol,2010, 6(11): 619-628.
[64] Dillinger JG, Drissa A, Sideris G,et al. Twice Daily Dosing of Aspirin Ii Biologically More Effective in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease[J].Circulation,2011, 124: A8537.
[65] Rocca B, SantilliF, Pitocco D,et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes[J].J Thromb Haemost,2012, 10(7): 1220-1230.
[66] Capodanno D, Patel A, Dharmashankar K, et al.Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease[J].Circ Cardiovasc Interv,2011, 4(2): 180-187.
[67] Serebruany VL, Malinin AI, Pokov A, et al.Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial[J].Am Heart J,2008, 155(1): 93 e91-97.
[68] Duzenli MA, Ozdemir K, Aygul N, et al.Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin[J].Am J Cardiol,2008, 102(4): 396-400.
[69] Coccheri S.Approaches to prevention of cardiovascular complications and events in diabetes mellitus[J].Drugs,2007, 67(7): 997-1026.
[70] Srikanth S, Deedwania P. Comprehensive risk reduction of cardiovascular risk factors in the diabetic patient: an integrated approach[J].Cardiol Clin,2005, 23(2): 193-210